Source: International Congress 2018 – Aspects of pulmonary rehabilitation and chronic care
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Papaioannou (Chaidari, Athens, Greece), E. Manali (Chaidari, Athens, Greece), P. Lyberopoulos (Chaidari, Athens, Greece), A. Papaporfyriou (Chaidari, Athens, Greece), M. Kallieri (Chaidari, Athens, Greece), S. Gyftopoulos (Athens, Greece), D. Konstantonis (Chaidari, Athens, Greece), E. Stagaki (Chaidari, Athens, Greece), G. Papadaki (Chaidari, Athens, Greece), K. Kostikas (Chaidari, Athens, Greece), R. Spetsioti (Athens, , Greece), I. Vogiatzis (Athens, , Greece), A. Mazioti (Chaidari, Athens, Greece), S. Loukides (Chaidari, Athens, Greece), S. Papiris (Chaidari, Athens, Greece). The effects of pulmonary rehabilitation in patients with Combined Pulmonary Fibrosis and Emphysema (CPFE). 4151

Member's Comments

No comment yet.

Related content which might interest you: Effect of pulmonary hemodynamics on the prognosis of patients with emphysematous COPD after LVRS Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Pulmonary hemodynamics and lung function in patients with COPD and DPLD Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Correlation between pulmonary function tests and HRCT indexes in Idiopathic Pulmonary Fibrosis (IPF) patients Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Relation between pulmonary arterial remodeling and parenchymal disease in severe COPD and interstitial lung disease patients Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Clinical data, lung function and cardiopulmonary exercise testing in CPFE (combined pulmonary fibrosis with emphysema). Results of a cohort of 20 patients Source: International Congress 2014 – ILDs 6 Year: 2014 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Courses: Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Pulmonary rehabilitation in IPF Source: International Congress 2018 – Interstitial lung disease: an interdisciplinary approach Year: 2018 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2014 – ILDs 1 Year: 2014 Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 The effect of pulmonary hypertension on aerobic exercise capacity in lung transplant candidates with advanced COPD Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Comparison of physiological impairment in ILD patients with and without diagnostic IPF features Source: International Congress 2014 – ILDs 4 Year: 2014 Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014